Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Financing Activities: 2022-2024

Historic Cash from Financing Activities for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to -$121.7 billion.

  • Addex Therapeutics' Cash from Financing Activities rose 97.97% to -$121.7 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 billion, marking a year-over-year increase of 101.60%. This contributed to the annual value of $119,260 for FY2024, which is 97.97% down from last year.
  • Addex Therapeutics' Cash from Financing Activities amounted to -$121.7 billion in Q4 2024, which was down 198.90% from $123.1 billion recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Cash from Financing Activities ranged from a high of $6,130.2 billion in Q2 2023 and a low of -$6,000.8 billion during Q4 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$150,642 (2022), whereas its average is -$6.9 billion.
  • Examining YoY changes over the last 5 years, Addex Therapeutics' Cash from Financing Activities showed a top increase of 3,467,833,889.64% in 2023 and a maximum decrease of 3,422,758,580.74% in 2023.
  • Over the past 3 years, Addex Therapeutics' Cash from Financing Activities (Quarterly) stood at -$175,322 in 2022, then slumped by 3,422,758,580.74% to -$6,000.8 billion in 2023, then skyrocketed by 97.97% to -$121.7 billion in 2024.
  • Its Cash from Financing Activities was -$121.7 billion in Q4 2024, compared to $123.1 billion in Q3 2024 and $195,259 in Q2 2024.